MX2023009281A - Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro. - Google Patents
Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro.Info
- Publication number
- MX2023009281A MX2023009281A MX2023009281A MX2023009281A MX2023009281A MX 2023009281 A MX2023009281 A MX 2023009281A MX 2023009281 A MX2023009281 A MX 2023009281A MX 2023009281 A MX2023009281 A MX 2023009281A MX 2023009281 A MX2023009281 A MX 2023009281A
- Authority
- MX
- Mexico
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
- 229960001058 bupropion Drugs 0.000 title abstract 7
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title abstract 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 229960001985 dextromethorphan Drugs 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se describen formas de dosificación de (S)-bupropión enriquecido enantioméricamente o (R)-bupropión enriquecido enantioméricamente. El (S)-bupropión o (R)-bupropión puede estar enriquecido con deuterio o pueden tener una abundancia isotópica natural. Estas formas de dosificación pueden administrarse, con la alimentación o en ayunas, para tratar una afección mencionada en la presente descripción, para lograr un cierto parámetro farmacocinético de un bupropión o un metabolito de un bupropión, y/o para mejorar los niveles plasmáticos de dextrometorfano.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009281A true MX2023009281A (es) | 2023-08-17 |
Family
ID=67688503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008704A MX2020008704A (es) | 2018-02-23 | 2019-02-25 | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. |
| MX2023009281A MX2023009281A (es) | 2018-02-23 | 2020-08-20 | Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008704A MX2020008704A (es) | 2018-02-23 | 2019-02-25 | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (es) |
| JP (3) | JP2021513998A (es) |
| KR (2) | KR20230075531A (es) |
| CN (1) | CN112087999A (es) |
| AU (2) | AU2019223187B2 (es) |
| BR (1) | BR112020017179A2 (es) |
| CA (1) | CA3092076A1 (es) |
| CL (1) | CL2020002166A1 (es) |
| CR (1) | CR20200415A (es) |
| EC (1) | ECSP20060179A (es) |
| IL (1) | IL276871A (es) |
| MA (1) | MA51914A (es) |
| MX (2) | MX2020008704A (es) |
| NI (1) | NI202000056A (es) |
| NZ (1) | NZ767378A (es) |
| PE (1) | PE20211752A1 (es) |
| SG (1) | SG11202008056SA (es) |
| WO (1) | WO2019165379A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| AU2020349419B2 (en) * | 2019-09-20 | 2023-11-02 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038502A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| PL196544B1 (pl) * | 2003-08-08 | 2008-01-31 | Biovail Lab Int Srl | Tabletka o zmodyfikowanym uwalnianiu |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
-
2019
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active IP Right Cessation
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko active Application Filing
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-08-23 IL IL276871A patent/IL276871A/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521A1/en active Pending
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ767378A (en) | 2024-03-22 |
| EP3755312A4 (en) | 2022-03-16 |
| IL276871A (en) | 2020-10-29 |
| NI202000056A (es) | 2021-01-11 |
| KR20210003091A (ko) | 2021-01-11 |
| PE20211752A1 (es) | 2021-09-06 |
| AU2022204521A1 (en) | 2022-07-21 |
| AU2019223187B2 (en) | 2022-07-28 |
| ECSP20060179A (es) | 2020-12-31 |
| CR20200415A (es) | 2021-02-03 |
| CN112087999A (zh) | 2020-12-15 |
| JP2022153638A (ja) | 2022-10-12 |
| EP3755312A1 (en) | 2020-12-30 |
| KR20230075531A (ko) | 2023-05-31 |
| JP2021513998A (ja) | 2021-06-03 |
| JP2024075655A (ja) | 2024-06-04 |
| CL2020002166A1 (es) | 2020-10-23 |
| WO2019165379A1 (en) | 2019-08-29 |
| MX2020008704A (es) | 2020-12-07 |
| CA3092076A1 (en) | 2019-08-29 |
| MA51914A (fr) | 2020-12-30 |
| SG11202008056SA (en) | 2020-09-29 |
| AU2019223187A1 (en) | 2020-09-17 |
| BR112020017179A2 (pt) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009281A (es) | Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro. | |
| JO3522B1 (ar) | تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له | |
| MX2018014202A (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| NZ610526A (en) | Deuterium enriched rasagiline | |
| MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| MX2019014113A (es) | Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar. | |
| AU2017247046A1 (en) | Synchronizing ancillary data to content including audio | |
| MX2023004028A (es) | Dispositivo y metodo para la dispersion de no de concentracion alta con gas de terapia de inhalacion. | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| GEP20227384B (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment | |
| MX2021001845A (es) | Un medicamento combinado que comprende fenilefrina y paracetamol. | |
| CR20220119A (es) | Formas de dosificación para bupropión enantioméricamente enriquecido o puro | |
| MX2018013324A (es) | Métodos y composiciones para el tratamiento del síndrome de rett. | |
| CR20200616A (es) | Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión | |
| Collins | Breathing difficulty and sedation: case report | |
| Vourvahis | Lersivirine/methadone | |
| Tomita | Thrombocytopenia, neutropenia and proteinuria: case report | |
| UA99842U (ru) | Способ проводниковой анестезии | |
| MX2018010367A (es) | Titulacion de cebranopadol. | |
| UA89024U (uk) | Спосіб комплексного лікування уретеролітіазу | |
| UA105586U (uk) | Спосіб лікування печінкової енцефалопатії | |
| UA93429U (uk) | Спосіб підвищення ефективності профілактики судинних ускладнень у хворих на остеоартроз |